multidisciplinary team Side-icon

AstraZeneca (Tropion 10) , NCT06357533

Brief Summary

The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.

Official Title

A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)

Conditions

Non-Small Cell Lung Cancer

COPERNICUS, NCT06667076

Brief Summary

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (COPERNICUS)

The primary purpose of the study is to assess how well amivantamab subcutaneous (SC) administration in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC; that is one of the major types of lung cancer).

Official Title

A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination With Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination With Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Conditions

Carcinoma, Non-Small-Cell Lung

multidisciplinary team Side-icon
multidisciplinary team Side-icon

Triton (NCT06008093)

Brief Summary

This is a Phase III randomized, double-blind study assessing the efficacy and safety of [specific treatment or drug] in patients with advanced non-small cell lung cancer (NSCLC). The trial aims to evaluate survival outcomes and quality of life improvements in participants receiving the intervention.

Official Title

A Phase III, Randomized, Double-Blind Study Evaluating [Full Study Title Placeholder] in Patients with Non-Small Cell Lung Cancer.

Conditions

Non-Small Cell Lung Cancer (NSCLC)